Sign in to see private stats on your profile page — or add photo, interests, videos, mentoring, etc.

    Martin McMahon, PhD

    TitleProfessor In Residence
    SchoolUCSF School of Medicine
    DepartmentHDF Comprehensive Cancer Ctr
    Address1450 3rd Street
    San Francisco CA 94158
    Phone801-213-5790
    vCardDownload vCard

      Collapse Biography 
      Collapse Education and Training
      University of California, San FranciscoPostdoctoral StudiesGraduate Division

      Collapse ORNG Applications 
      Collapse Websites
      Collapse Awarded Grants
      Collapse Global Health
      Collapse Featured Videos

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Grossauer S, Koeck K, Murphy NE, Meyers ID, Daynac M, Truffaux N, Truong AY, Nicolaides TP, McMahon M, Berger MS, Phillips JJ, James CD, Petritsch CK. Concurrent MEK targeted therapy prevents MAPK pathway reactivation during BRAFV600E targeted inhibition in a novel syngeneic murine glioma model. Oncotarget. 2016 Oct 3. PMID: 27713119.
        View in: PubMed
      2. van Veen JE, Pringle DR, McMahon M. P2A-Fluorophore Tagging of BRAF Tightly Links Expression to Fluorescence In Vivo. PLoS One. 2016; 11(6):e0157661. PMID: 27348307.
        View in: PubMed
      3. Merlino G, Herlyn M, Fisher DE, Bastian BC, Flaherty KT, Davies MA, Wargo JA, Curiel-Lewandrowski C, Weber MJ, Leachman SA, Soengas MS, McMahon M, Harbour JW, Swetter SM, Aplin AE, Atkins MB, Bosenberg MW, Dummer R, Gershenwald JE, Halpern AC, Herlyn D, Karakousis GC, Kirkwood JM, Krauthammer M, Lo RS, Long GV, McArthur G, Ribas A, Schuchter L, Sosman JA, Smalley KS, Steeg P, Thomas NE, Tsao H, Tueting T, Weeraratna A, Xu G, Lomax R, Martin A, Silverstein S, Turnham T, Ronai ZA. The state of melanoma: challenges and opportunities. Pigment Cell Melanoma Res. 2016 Jul; 29(4):404-16. PMID: 27087480.
        View in: PubMed
      4. Green S, Trejo CL, McMahon M. PIK3CAH1047R Accelerates and Enhances KRASG12D-Driven Lung Tumorigenesis. Cancer Res. 2015 Dec 15; 75(24):5378-91. PMID: 26567140.
        View in: PubMed
      5. Cho JH, Robinson JP, Arave RA, Burnett WJ, Kircher DA, Chen G, Davies MA, Grossmann AH, VanBrocklin MW, McMahon M, Holmen SL. AKT1 Activation Promotes Development of Melanoma Metastases. Cell Rep. 2015 Nov 3; 13(5):898-905. PMID: 26565903; PMCID: PMC4646731.
      6. Shai A, Dankort D, Juan J, Green S, McMahon M. TP53 Silencing Bypasses Growth Arrest of BRAFV600E-Induced Lung Tumor Cells in a Two-Switch Model of Lung Tumorigenesis. Cancer Res. 2015 Aug 1; 75(15):3167-80. PMID: 26001956; PMCID: PMC4526430 [Available on 08/01/16].
      7. Deuker MM, McMahon M. Rational targeting of BRAF and PI3-Kinase signaling for melanoma therapy. Mol Cell Oncol. 2016 May; 3(3):e1033095. PMID: 27314067.
        View in: PubMed
      8. Lin L, Sabnis AJ, Chan E, Olivas V, Cade L, Pazarentzos E, Asthana S, Neel D, Yan JJ, Lu X, Pham L, Wang MM, Karachaliou N, Cao MG, Manzano JL, Ramirez JL, Torres JM, Buttitta F, Rudin CM, Collisson EA, Algazi A, Robinson E, Osman I, Muñoz-Couselo E, Cortes J, Frederick DT, Cooper ZA, McMahon M, Marchetti A, Rosell R, Flaherty KT, Wargo JA, Bivona TG. The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies. Nat Genet. 2015 Mar; 47(3):250-6. PMID: 25665005.
        View in: PubMed
      9. Damsky W, Micevic G, Meeth K, Muthusamy V, Curley DP, Santhanakrishnan M, Erdelyi I, Platt JT, Huang L, Theodosakis N, Zaidi MR, Tighe S, Davies MA, Dankort D, McMahon M, Merlino G, Bardeesy N, Bosenberg M. mTORC1 activation blocks BrafV600E-induced growth arrest but is insufficient for melanoma formation. Cancer Cell. 2015 Jan 12; 27(1):41-56. PMID: 25584893; PMCID: PMC4295062 [Available on 01/12/16].
      10. Deuker MM, Marsh Durban V, Phillips WA, McMahon M. PI3'-kinase inhibition forestalls the onset of MEK1/2 inhibitor resistance in BRAF-mutated melanoma. Cancer Discov. 2015 Feb; 5(2):143-53. PMID: 25472943; PMCID: PMC4320669.
      11. Holderfield M, Deuker MM, McCormick F, McMahon M. Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nat Rev Cancer. 2014 Jul; 14(7):455-67. PMID: 24957944; PMCID: PMC4250230.
      12. Deuker MM, McMahon M. Cancer biology: Enzyme meets a surprise target. Nature. 2014 Jun 12; 510(7504):225-6. PMID: 24847879; PMCID: PMC4250228.
      13. Cooper ZA, Juneja VR, Sage PT, Frederick DT, Piris A, Mitra D, Lo JA, Hodi FS, Freeman GJ, Bosenberg MW, McMahon M, Flaherty KT, Fisher DE, Sharpe AH, Wargo JA. Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade. Cancer Immunol Res. 2014 Jul; 2(7):643-54. PMID: 24903021; PMCID: PMC4097121.
      14. Charles RP, Silva J, Iezza G, Phillips WA, McMahon M. Activating BRAF and PIK3CA mutations cooperate to promote anaplastic thyroid carcinogenesis. Mol Cancer Res. 2014 Jul; 12(7):979-86. PMID: 24770869; PMCID: PMC4635659.
      15. Luo X, Mitra D, Sullivan RJ, Wittner BS, Kimura AM, Pan S, Hoang MP, Brannigan BW, Lawrence DP, Flaherty KT, Sequist LV, McMahon M, Bosenberg MW, Stott SL, Ting DT, Ramaswamy S, Toner M, Fisher DE, Maheswaran S, Haber DA. Isolation and molecular characterization of circulating melanoma cells. Cell Rep. 2014 May 8; 7(3):645-53. PMID: 24746818; PMCID: PMC4079008.
      16. McFadden DG, Vernon A, Santiago PM, Martinez-McFaline R, Bhutkar A, Crowley DM, McMahon M, Sadow PM, Jacks T. p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer. Proc Natl Acad Sci U S A. 2014 Apr 22; 111(16):E1600-9. PMID: 24711431; PMCID: PMC4000830.
      17. Juan J, Muraguchi T, Iezza G, Sears RC, McMahon M. Diminished WNT -> ß-catenin -> c-MYC signaling is a barrier for malignant progression of BRAFV600E-induced lung tumors. Genes Dev. 2014 Mar 15; 28(6):561-75. PMID: 24589553; PMCID: PMC3967046.
      18. Silva JM, McMahon M. The fastest Western in town: a contemporary twist on the classic Western blot analysis. J Vis Exp. 2014; (84):e51149. PMID: 24561642; PMCID: PMC4028330.
      19. Silva JM, Bulman C, McMahon M. BRAFV600E cooperates with PI3K signaling, independent of AKT, to regulate melanoma cell proliferation. Mol Cancer Res. 2014 Mar; 12(3):447-63. PMID: 24425783; PMCID: PMC3966216.
      20. Marsh Durban V, Deuker MM, Bosenberg MW, Phillips W, McMahon M. Differential AKT dependency displayed by mouse models of BRAFV600E-initiated melanoma. J Clin Invest. 2013 Dec; 123(12):5104-18. PMID: 24200692; PMCID: PMC3859393.
      21. Kamata T, Dankort D, Kang J, Giblett S, Pritchard CA, McMahon M, Leavitt AD. Hematopoietic expression of oncogenic BRAF promotes aberrant growth of monocyte-lineage cells resistant to PLX4720. Mol Cancer Res. 2013 Dec; 11(12):1530-41. PMID: 24152792; PMCID: PMC3869667.
      22. Yuan P, Ito K, Perez-Lorenzo R, Del Guzzo C, Lee JH, Shen CH, Bosenberg MW, McMahon M, Cantley LC, Zheng B. Phenformin enhances the therapeutic benefit of BRAF(V600E) inhibition in melanoma. Proc Natl Acad Sci U S A. 2013 Nov 5; 110(45):18226-31. PMID: 24145418; PMCID: PMC3831456.
      23. Goodwin AF, Tidyman WE, Jheon AH, Sharir A, Zheng X, Charles C, Fagin JA, McMahon M, Diekwisch TG, Ganss B, Rauen KA, Klein OD. Abnormal Ras signaling in Costello syndrome (CS) negatively regulates enamel formation. Hum Mol Genet. 2014 Feb 1; 23(3):682-92. PMID: 24057668; PMCID: PMC3888259.
      24. Trejo CL, Green S, Marsh V, Collisson EA, Iezza G, Phillips WA, McMahon M. Mutationally activated PIK3CA(H1047R) cooperates with BRAF(V600E) to promote lung cancer progression. Cancer Res. 2013 Nov 1; 73(21):6448-61. PMID: 24019382; PMCID: PMC3825323.
      25. Strohecker AM, Guo JY, Karsli-Uzunbas G, Price SM, Chen GJ, Mathew R, McMahon M, White E. Autophagy sustains mitochondrial glutamine metabolism and growth of BrafV600E-driven lung tumors. Cancer Discov. 2013 Nov; 3(11):1272-85. PMID: 23965987; PMCID: PMC3823822.
      26. Das Thakur M, Salangsang F, Landman AS, Sellers WR, Pryer NK, Levesque MP, Dummer R, McMahon M, Stuart DD. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature. 2013 Feb 14; 494(7436):251-5. PMID: 23302800; PMCID: PMC3930354.
      27. Maertens O, Johnson B, Hollstein P, Frederick DT, Cooper ZA, Messiaen L, Bronson RT, McMahon M, Granter S, Flaherty K, Wargo JA, Marais R, Cichowski K. Elucidating distinct roles for NF1 in melanomagenesis. Cancer Discov. 2013 Mar; 3(3):338-49. PMID: 23171796; PMCID: PMC3595355.
      28. Mito JK, Min HD, Ma Y, Carter JE, Brigman BE, Dodd L, Dankort D, McMahon M, Kirsch DG. Oncogene-dependent control of miRNA biogenesis and metastatic progression in a model of undifferentiated pleomorphic sarcoma. J Pathol. 2013 Jan; 229(1):132-40. PMID: 22951975; PMCID: PMC3552559.
      29. Mitra D, Luo X, Morgan A, Wang J, Hoang MP, Lo J, Guerrero CR, Lennerz JK, Mihm MC, Wargo JA, Robinson KC, Devi SP, Vanover JC, D'Orazio JA, McMahon M, Bosenberg MW, Haigis KM, Haber DA, Wang Y, Fisher DE. An ultraviolet-radiation-independent pathway to melanoma carcinogenesis in the red hair/fair skin background. Nature. 2012 Nov 15; 491(7424):449-53. PMID: 23123854; PMCID: PMC3521494.
      30. Andreadi C, Cheung LK, Giblett S, Patel B, Jin H, Mercer K, Kamata T, Lee P, Williams A, McMahon M, Marais R, Pritchard C. The intermediate-activity (L597V)BRAF mutant acts as an epistatic modifier of oncogenic RAS by enhancing signaling through the RAF/MEK/ERK pathway. Genes Dev. 2012 Sep 1; 26(17):1945-58. PMID: 22892241; PMCID: PMC3435497.
      31. Gysin S, Paquette J, McMahon M. Analysis of mRNA profiles after MEK1/2 inhibition in human pancreatic cancer cell lines reveals pathways involved in drug sensitivity. Mol Cancer Res. 2012 Dec; 10(12):1607-19. PMID: 22833572; PMCID: PMC4261949.
      32. Wang J, Kobayashi T, Floc'h N, Kinkade CW, Aytes A, Dankort D, Lefebvre C, Mitrofanova A, Cardiff RD, McMahon M, Califano A, Shen MM, Abate-Shen C. B-Raf activation cooperates with PTEN loss to drive c-Myc expression in advanced prostate cancer. Cancer Res. 2012 Sep 15; 72(18):4765-76. PMID: 22836754; PMCID: PMC3445712.
      33. Tien AC, Tsai HH, Molofsky AV, McMahon M, Foo LC, Kaul A, Dougherty JD, Heintz N, Gutmann DH, Barres BA, Rowitch DH. Regulated temporal-spatial astrocyte precursor cell proliferation involves BRAF signalling in mammalian spinal cord. Development. 2012 Jul; 139(14):2477-87. PMID: 22675209; PMCID: PMC3383225.
      34. Collisson EA, Trejo CL, Silva JM, Gu S, Korkola JE, Heiser LM, Charles RP, Rabinovich BA, Hann B, Dankort D, Spellman PT, Phillips WA, Gray JW, McMahon M. A central role for RAF?MEK?ERK signaling in the genesis of pancreatic ductal adenocarcinoma. Cancer Discov. 2012 Aug; 2(8):685-93. PMID: 22628411; PMCID: PMC3425446.
      35. Huillard E, Hashizume R, Phillips JJ, Griveau A, Ihrie RA, Aoki Y, Nicolaides T, Perry A, Waldman T, McMahon M, Weiss WA, Petritsch C, James CD, Rowitch DH. Cooperative interactions of BRAFV600E kinase and CDKN2A locus deficiency in pediatric malignant astrocytoma as a basis for rational therapy. Proc Natl Acad Sci U S A. 2012 May 29; 109(22):8710-5. PMID: 22586120; PMCID: PMC3365162.
      36. Vredeveld LC, Possik PA, Smit MA, Meissl K, Michaloglou C, Horlings HM, Ajouaou A, Kortman PC, Dankort D, McMahon M, Mooi WJ, Peeper DS. Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis. Genes Dev. 2012 May 15; 26(10):1055-69. PMID: 22549727; PMCID: PMC3360561.
      37. Li CY, Cha W, Luder HU, Charles RP, McMahon M, Mitsiadis TA, Klein OD. E-cadherin regulates the behavior and fate of epithelial stem cells and their progeny in the mouse incisor. Dev Biol. 2012 Jun 15; 366(2):357-66. PMID: 22537490; PMCID: PMC3690274.
      38. Trejo CL, Juan J, Vicent S, Sweet-Cordero A, McMahon M. MEK1/2 inhibition elicits regression of autochthonous lung tumors induced by KRASG12D or BRAFV600E. Cancer Res. 2012 Jun 15; 72(12):3048-59. PMID: 22511580; PMCID: PMC3393094.
      39. Damsky WE, Curley DP, Santhanakrishnan M, Rosenbaum LE, Platt JT, Gould Rothberg BE, Taketo MM, Dankort D, Rimm DL, McMahon M, Bosenberg M. ß-catenin signaling controls metastasis in Braf-activated Pten-deficient melanomas. Cancer Cell. 2011 Dec 13; 20(6):741-54. PMID: 22172720; PMCID: PMC3241928.
      40. Tang N, Marshall WF, McMahon M, Metzger RJ, Martin GR. Control of mitotic spindle angle by the RAS-regulated ERK1/2 pathway determines lung tube shape. Science. 2011 Jul 15; 333(6040):342-5. PMID: 21764747; PMCID: PMC4260627.
      41. Charles RP, Iezza G, Amendola E, Dankort D, McMahon M. Mutationally activated BRAF(V600E) elicits papillary thyroid cancer in the adult mouse. Cancer Res. 2011 Jun 1; 71(11):3863-71. PMID: 21512141; PMCID: PMC3107361.
      42. Rauen KA, Banerjee A, Bishop WR, Lauchle JO, McCormick F, McMahon M, Melese T, Munster PN, Nadaf S, Packer RJ, Sebolt-Leopold J, Viskochil DH. Costello and cardio-facio-cutaneous syndromes: Moving toward clinical trials in RASopathies. Am J Med Genet C Semin Med Genet. 2011 May 15; 157C(2):136-46. PMID: 21495172; PMCID: PMC4145816.
      43. McMahon M. Parsing out the complexity of RAF inhibitor resistance. Pigment Cell Melanoma Res. 2011 Apr; 24(2):361-5. PMID: 21392366; PMCID: PMC3075071.
      44. McMahon M. RAF translocations expand cancer targets. Nat Med. 2010 Jul; 16(7):749-50. PMID: 20613748; PMCID: PMC4263025.
      45. Amin DN, Sergina N, Ahuja D, McMahon M, Blair JA, Wang D, Hann B, Koch KM, Shokat KM, Moasser MM. Resiliency and vulnerability in the HER2-HER3 tumorigenic driver. Sci Transl Med. 2010 Jan 27; 2(16):16ra7. PMID: 20371474; PMCID: PMC3033659.
      46. Held MA, Curley DP, Dankort D, McMahon M, Muthusamy V, Bosenberg MW. Characterization of melanoma cells capable of propagating tumors from a single cell. Cancer Res. 2010 Jan 1; 70(1):388-97. PMID: 20048081; PMCID: PMC4026296.
      47. Rauen KA, Schoyer L, McCormick F, Lin AE, Allanson JE, Stevenson DA, Gripp KW, Neri G, Carey JC, Legius E, Tartaglia M, Schubbert S, Roberts AE, Gelb BD, Shannon K, Gutmann DH, McMahon M, Guerra C, Fagin JA, Yu B, Aoki Y, Neel BG, Balmain A, Drake RR, Nolan GP, Zenker M, Bollag G, Sebolt-Leopold J, Gibbs JB, Silva AJ, Patton EE, Viskochil DH, Kieran MW, Korf BR, Hagerman RJ, Packer RJ, Melese T. Proceedings from the 2009 genetic syndromes of the Ras/MAPK pathway: From bedside to bench and back. Am J Med Genet A. 2010 Jan; 152A(1):4-24. PMID: 20014119; PMCID: PMC4051786.
      48. Krueger F, Madeja Z, Hemberger M, McMahon M, Cook SJ, Gaunt SJ. Down-regulation of Cdx2 in colorectal carcinoma cells by the Raf-MEK-ERK 1/2 pathway. Cell Signal. 2009 Dec; 21(12):1846-56. PMID: 19686845; PMCID: PMC4625762.
      49. Agarwala SS, Becker JC, Eggermont AM, Flaherty KT, Garbe C, Goldstein AM, Halpern A, Kashani-Sabet M, Hauschild A, Kirkwood JM, Leachman S, Lorigan P, McMahon M, Messina J, Ribas A, Samlowski WE, Schadendorf D, Sondak VK. Meeting report: consensus from the first and second Global Workshops in Melanoma November 19-20, 2008. Pigment Cell Melanoma Res. 2009 Oct; 22(5):532-43. PMID: 19659612.
        View in: PubMed
      50. Dankort D, Curley DP, Cartlidge RA, Nelson B, Karnezis AN, Damsky WE, You MJ, DePinho RA, McMahon M, Bosenberg M. Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet. 2009 May; 41(5):544-52. PMID: 19282848; PMCID: PMC2705918.
      51. Fisher DE, Medrano EE, McMahon M, Soengas MS, Schuchter L, Wolchok JD, Merlino G. Meeting report: fourth international congress of the Society for Melanoma Research. Pigment Cell Melanoma Res. 2008 Feb; 21(1):15-26. PMID: 18353140.
        View in: PubMed
      52. Cartlidge RA, Thomas GR, Cagnol S, Jong KA, Molton SA, Finch AJ, McMahon M. Oncogenic BRAF(V600E) inhibits BIM expression to promote melanoma cell survival. Pigment Cell Melanoma Res. 2008 Oct; 21(5):534-44. PMID: 18715233.
        View in: PubMed
      53. Dankort D, Filenova E, Collado M, Serrano M, Jones K, McMahon M. A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors. Genes Dev. 2007 Feb 15; 21(4):379-84. PMID: 17299132; PMCID: PMC1804325.
      54. Levin M, Ewald AJ, McMahon M, Werb Z, Mostov K. A model of intussusceptive angiogenesis. Novartis Found Symp. 2007; 283:37-42; discussion 42-5, 238-41. PMID: 18300412.
        View in: PubMed
      55. Banerjee A, Gugasyan R, McMahon M, Gerondakis S. Diverse Toll-like receptors utilize Tpl2 to activate extracellular signal-regulated kinase (ERK) in hemopoietic cells. Proc Natl Acad Sci U S A. 2006 Feb 28; 103(9):3274-9. PMID: 16484370; PMCID: PMC1413910.
      56. Brandts CH, Sargin B, Rode M, Biermann C, Lindtner B, Schwäble J, Buerger H, Müller-Tidow C, Choudhary C, McMahon M, Berdel WE, Serve H. Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and myeloid transformation. Cancer Res. 2005 Nov 1; 65(21):9643-50. PMID: 16266983.
        View in: PubMed
      57. Gysin S, Rickert P, Kastury K, McMahon M. Analysis of genomic DNA alterations and mRNA expression patterns in a panel of human pancreatic cancer cell lines. Genes Chromosomes Cancer. 2005 Sep; 44(1):37-51. PMID: 15929091.
        View in: PubMed
      58. Shelton JG, Steelman LS, Abrams SL, White ER, Akula SM, Franklin RA, Bertrand FE, McMahon M, McCubrey JA. Conditional EGFR promotes cell cycle progression and prevention of apoptosis in the absence of autocrine cytokines. Cell Cycle. 2005 Jun; 4(6):822-30. PMID: 15917660.
        View in: PubMed
      59. Gysin S, Lee SH, Dean NM, McMahon M. Pharmacologic inhibition of RAF-->MEK-->ERK signaling elicits pancreatic cancer cell cycle arrest through induced expression of p27Kip1. Cancer Res. 2005 Jun 1; 65(11):4870-80. PMID: 15930308.
        View in: PubMed
      60. Sreeramaneni R, Chaudhry A, McMahon M, Sherr CJ, Inoue K. Ras-Raf-Arf signaling critically depends on the Dmp1 transcription factor. Mol Cell Biol. 2005 Jan; 25(1):220-32. PMID: 15601844; PMCID: PMC538777.
      61. Mirza AM, Gysin S, Malek N, Nakayama K, Roberts JM, McMahon M. Cooperative regulation of the cell division cycle by the protein kinases RAF and AKT. Mol Cell Biol. 2004 Dec; 24(24):10868-81. PMID: 15572689; PMCID: PMC533961.
      62. McCubrey JA, Shelton JG, Steelman LS, Franklin RA, Sreevalsan T, McMahon M. Effects of a conditionally active v-ErbB and an EGF-R inhibitor on transformation of NIH-3T3 cells and abrogation of cytokine dependency of hematopoietic cells. Oncogene. 2004 Oct 14; 23(47):7810-20. PMID: 15361836.
        View in: PubMed
      63. Silletti S, Yebra M, Perez B, Cirulli V, McMahon M, Montgomery AM. Extracellular signal-regulated kinase (ERK)-dependent gene expression contributes to L1 cell adhesion molecule-dependent motility and invasion. J Biol Chem. 2004 Jul 9; 279(28):28880-8. PMID: 15128735.
        View in: PubMed
      64. Bergo MO, Gavino BJ, Hong C, Beigneux AP, McMahon M, Casey PJ, Young SG. Inactivation of Icmt inhibits transformation by oncogenic K-Ras and B-Raf. J Clin Invest. 2004 Feb; 113(4):539-50. PMID: 14966563; PMCID: PMC338259.
      65. Balmanno K, Millar T, McMahon M, Cook SJ. DeltaRaf-1:ER* bypasses the cyclic AMP block of extracellular signal-regulated kinase 1 and 2 activation but not CDK2 activation or cell cycle reentry. Mol Cell Biol. 2003 Dec; 23(24):9303-17. PMID: 14645540; PMCID: PMC309715.
      66. Thayer SP, di Magliano MP, Heiser PW, Nielsen CM, Roberts DJ, Lauwers GY, Qi YP, Gysin S, Fernández-del Castillo C, Yajnik V, Antoniu B, McMahon M, Warshaw AL, Hebrok M. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature. 2003 Oct 23; 425(6960):851-6. PMID: 14520413; PMCID: PMC3688051.
      67. Woodrow MA, Woods D, Cherwinski HM, Stokoe D, McMahon M. Ras-induced serine phosphorylation of the focal adhesion protein paxillin is mediated by the Raf-->MEK-->ERK pathway. Exp Cell Res. 2003 Jul 15; 287(2):325-38. PMID: 12837288.
        View in: PubMed
      68. Anders M, Christian C, McMahon M, McCormick F, Korn WM. Inhibition of the Raf/MEK/ERK pathway up-regulates expression of the coxsackievirus and adenovirus receptor in cancer cells. Cancer Res. 2003 May 1; 63(9):2088-95. PMID: 12727824.
        View in: PubMed
      69. Shelton JG, Steelman LS, Lee JT, Knapp SL, Blalock WL, Moye PW, Franklin RA, Pohnert SC, Mirza AM, McMahon M, McCubrey JA. Effects of the RAF/MEK/ERK and PI3K/AKT signal transduction pathways on the abrogation of cytokine-dependence and prevention of apoptosis in hematopoietic cells. Oncogene. 2003 Apr 24; 22(16):2478-92. PMID: 12717425.
        View in: PubMed
      70. Lagunoff M, Bechtel J, Venetsanakos E, Roy AM, Abbey N, Herndier B, McMahon M, Ganem D. De novo infection and serial transmission of Kaposi's sarcoma-associated herpesvirus in cultured endothelial cells. J Virol. 2002 Mar; 76(5):2440-8. PMID: 11836422; PMCID: PMC153827.
      71. Venetsanakos E, Mirza A, Fanton C, Romanov SR, Tlsty T, McMahon M. Induction of tubulogenesis in telomerase-immortalized human microvascular endothelial cells by glioblastoma cells. Exp Cell Res. 2002 Feb 1; 273(1):21-33. PMID: 11795943.
        View in: PubMed
      Martin's Networks
      Related Concepts
      Derived automatically from this person's publications.
      _
      Co-Authors
      People in Profiles who have published with this person.
      _
      Related Authors
      People who share related concepts with this person.
      _
      Back to TOP